Tech Times on MSN
Nasal mRNA drug cuts common cold virus load 40-fold in asthma patients, validating COVID-vaccine technology as a respiratory antiviral
Intranasal mRNA therapy for asthma reduced rhinovirus viral load 40-fold versus placebo in a Phase 2a trial, Ethris announced November 5. The drug, ETH47, also cut lower respiratory symptoms 58% and ...
After a rhinovirus challenge, numerical reductions in respiratory symptoms were found with a nasally delivered messenger RNA ...
Experts at Johns Hopkins Bloomberg School of Public Health are urging people to get their annual flu shot before flu cases ...
Visionary investment in mRNA technology platforms is allowing ST PHARM and its two startups, Levatio Therapeutics and ...
In a study published earlier this year in the New England Journal of Medicine, the mRNA-1010 mRNA influenza vaccine prevented disease in adults 50 years and older more effectively than standard ...
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory ...
Asianet Newsable on MSN
Why did MRNA, XERS, VIR stocks surge to 52-week highs last week?
Moderna, Xeris Biopharma, and Vir Biotechnology shares surged to annual highs on Friday as Wall Street optimism grew and ...
Researchers have been chasing the dream of a cancer vaccine for decades. Some recent successes with mRNA technology are ...
Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results